[Federal Register Volume 89, Number 120 (Friday, June 21, 2024)]
[Notices]
[Page 52022]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-13534]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-34-2024]


Foreign-Trade Zone (FTZ) 29, Notification of Proposed Production 
Activity; Catalent Pharma Solutions, LLC (Catalent); (Nonsteroidal 
Antiandrogen Tablets); Winchester, Kentucky

    Catalent submitted a notification of proposed production activity 
to the FTZ Board (the Board) for its facility in Winchester, Kentucky 
within FTZ 29. The notification conforming to the requirements of the 
Board's regulations (15 CFR 400.22) was received on June 11, 2024.
    Pursuant to 15 CFR 400.14(b), FTZ production activity would be 
limited to the specific foreign-status material(s)/component(s) and 
specific finished product(s) described in the submitted notification 
(summarized below) and subsequently authorized by the Board. The 
benefits that may stem from conducting production activity under FTZ 
procedures are explained in the background section of the Board's 
website--accessible via www.trade.gov/ftz.
    The proposed finished products include: nonsteroidal antiandrogen 
tablets (duty-free).
    The proposed foreign-status materials/components include: 
apalutamide (active pharmaceutical ingredient) (duty rate of 6.5%).
    Public comment is invited from interested parties. Submissions 
shall be addressed to the Board's Executive Secretary and sent to: 
[email protected]. The closing period for their receipt is July 31, 2024.
    A copy of the notification will be available for public inspection 
in the ``Online FTZ Information System'' section of the Board's 
website.
    For further information, contact Kolade Osho at 
[email protected].

    Dated: June 14, 2024.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2024-13534 Filed 6-20-24; 8:45 am]
BILLING CODE 3510-DS-P